SFX by Ex Libris Inc.

Title:	Discovery of a Tetrahydropyrimidin-2(1H)-one Derivative (TAK-442) as a Potent, Selective, and Orally Active Factor Xa Inhibitor
Source:	Journal of Medicinal Chemistry [0022-2623] Fujimoto, Takuya yr:2010

Basic

Full text

Full text available via American Chemical Society Journals

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Gibson, J L m. "Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial." The Lancet 374.9683 (2009): 29-38.
description	2.	Hu, T. "Synthesis of Impurities of Pramipexole Dihydrochloride." Organic process research & development 20.11: 1899-1905.
description	3.	Bisai, V. "Methoxypyridines in the Synthesis of Lycopodium Alkaloids: Total Synthesis of (+/-)-Lycoposerramine R." Organic letters 12.11 (2010): 2551-2553.
description	4.	Kawamura, M. "Antithrombotic and Anticoagulant Profiles of TAK-442, a Novel Factor Xa Inhibitor, in a Rabbit Model of Venous Thrombosis." Journal of cardiovascular pharmacology 56.2 (2010): 156-161.
description	5.	Gurm, Hitinder S. "Rivaroxaban in acute coronary syndromes: too soon to know?" The Lancet 374.9683 (2009): 3-4.
description	6.	Mega, Jessica L. "Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction: Results From the ATLAS ACS-2-TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thro." Journal of the American College of Cardiology 61.18 (2013): 1853-1859.
description	7.	Turpie, Alexander G G G. "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial." The Lancet 373.9676 (2009): 1673-80.
description	8.	Segers, A. "A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study." Blood 112.6 (2008): 2242-7.
description	9.	Koch, V. "Cobalt-Catalyzed α-Arylation of Substituted α-Halogeno β-Lactams." Organic Letters 21.16 (2019): 6241-6244.
description	10.	"Sulfonate ester radical ion chemistry." Journal of organic chemistry. 54.14: 3256-3258.
description	11.	Holder, Jeffrey C. "A catalytic, enantioselective formal synthesis of (+)-dichroanone and (+)-taiwaniaquinone H." Organic letters 16.24 (2014): 6362-5.
description	12.	Morishima, Y. "[Research and development strategy of antithrombotic agents: pharmacology of the oral factor Xa-inhibitor edoxaban]." 日本薬理学会部会（日本薬理学雑誌） 136.2 (2010): 83-87.
description	13.	Mousa, Shaker A. "Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban." Methods in molecular biology 663 (2010): 181-201.
description	14.	Takahashi, N. "Catalytic Asymmetric Conjugate Addition of alpha-Cyanoketones for the Construction of a Quaternary Stereogenic Center." Organic letters 12.7 (2010): 1484-1487.
description	15.	Abcede, Hermelinda G. "Update on Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation." Current Treatment Options in Cardiovascular Medicine 12.3 (2010): 250-260.
description	16.	von Degenfeld, F. "Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?" Thrombosis and haemostasis 102.5 (2009): 892-899.
description	17.	Wood, Jessica L. "Synthesis of the tetracyclic core of the neomangicols using a late-stage indene alkylation." Organic letters 11.14 (2009): 3128-3131.
description	18.	McMurray, John J V J. "Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial." The Lancet 373.9681 (2009): 2125-35.
description	19.	Fukuzaki, T. "Studies aimed at the total synthesis of azadirachtin. A modeled connection of C-8 and C-14 in azadirachtin." Organic letters 4.17 (2002): 2877-2880.
description	20.	Vincent, Stella H. "Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans." Drug metabolism and disposition 35.4 (2007): 533-8.